This program was made possible by ZAXINE.
Irritable Bowel Syndrome (IBS) is one of the most common gastrointestinal (GI) disorders, with a prevalence of 10–15% recorded globally (18% in Canada), placing a considerable burden on healthcare systems. IBS can erode an individual’s productivity and quality of life.
ZAXINE is an antibacterial agent that acts locally on the microflora of the gut1*
Should not be used for the treatment of systemic bacterial infections
This co-pay program is available for the use of ZAXINE in the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.